missing translation for 'onlineSavingsMsg'
Learn More
Please login to your online account to display your discounted pricing

CD262 (DR5) Mouse anti-Human, PE, Clone: DJR2-4 (7-8), eBioscience™

Mouse Monoclonal Antibody

Manufacturer:  Life Technologies LS12990842

 View more versions of this product

Catalog No. 5011276



Description

Description

Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis. Applications Tested: This DJR2-4 (a.k.a. 7-8) antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μL (0.25 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.
Specifications

Specifications

CD262 (DR5)
Monoclonal
5 μL/Test
PBS with 0.1% gelatin, 0.2% BSA and 0.09% sodium azide; pH 7.2
O14763
CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9, Trail receptor 2
Mouse
Affinity chromatography
RUO
Antibody
Monoclonal
Human
Flow Cytometry
DJR2-4 (7-8)
PE
TNFRSF10B
Liquid
TNFRSF10B
IgG1, kappa
100 Tests
4° C, store in dark, DO NOT FREEZE!
Primary
8795
Documents

For Research Use Only.